Currently, anti-MDM2 drugs are in the developmental phase, undergoing clinical trials with promising results, especially for tumors that are inoperable, advanced, metastatic, aggressive, and associated with a poor prognosis, such as dedifferentiated liposarcoma (DDLPS), for instance. Here, MDM2 is linked to dedifferentiated liposarcoma.